The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Airlines Hit As UK Quarantine List Grows

Fri, 14th Aug 2020 10:56

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - LOSERS

----------

International Consolidated Airlines, down 6.5%. Shares in the British Airways parent were lower after the UK added France to its 14-day quarantine list. People arriving in the UK after 0400 BST on Saturday will be required to spend 14 days in self-isolation due to rising numbers of coronavirus cases in France. The conditions will also apply to travellers returning to the UK from the Netherlands, Monaco, Malta, Turks & Caicos and Aruba. The move, which applies throughout the UK, comes after Prime Minister Boris Johnson promised to be "absolutely ruthless" in decisions about imposing quarantine restrictions on countries. "The problem for the airlines is that people's desire for a break in the sun may be outweighed by their fear of the logistical challenges of holing up for two weeks when they get back, with decisions on which countries to add to the quarantine list often coming at short notice. This decision will feel particularly painful as it comes at the height of the UK holiday season and the question now becomes just how long the likes of EasyJet, Ryanair and British Airways-owner IAG can continue under these conditions," AJ Bell's Russ Mould commented.

----------

FTSE 250 - WINNERS

----------

Rank Group, up 3.5%. Shares in the gambling company were higher ahead of the reopening of casinos in the UK this weekend, as lockdown restrictions ease further. Under social distancing rules, casinos in the UK will reopen on Saturday for the first time since the lockdown was imposed. Rank Group owns Grosvenor Casinos, the largest UK casino operator with 52 casinos nationwide and Mecca Bingo, the UK's leading bingo operator.

----------

FTSE 250 - LOSERS

----------

easyJet, down 7.5%, Tui, down 5.8%. The travel stocks were dealt a blow by the UK government decision to add France to the quarantine list. "With France being added to the quarantine list for the UK, travel & leisure is under pressure. Shares in IAG, Ryanair, Tui and EasyJet were all sharply lower as the move will force a large swathe of cancellations right at the peak of the summer holiday season for one of the largest markets for UK tourists. Half a million Brits are thought to be in France right now," said Markets.com analyst Neil Wilson. Elsewhere, Irish carrier Ryanair Holdings was down 4.9% and Dart Group, which owns the Jet2 airline, was down 9.5%.

----------

WH Smith, down 5.5%. Shares in the books, magazines and confectionery retailer were also lower as part of the UK's new quarantine travel rules. WH Smith generates a substantial amount of its revenue from stores in airports and train stations. "Related stocks were also hit. WH Smith - purveyor of overpriced sweets and Evian - slipped down the board as a result. Apart from the immediate damage this will do at the height of the school holidays and peak summer season, the quarantine decision also underlines the inherent risk you take in booking a holiday abroad right now, which will do nothing for consumer confidence," Wilson added.

----------

Domino's Pizza, down 5.5%. Citigroup downgraded the pizza delivery chain to Sell from Neutral.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Verona Pharma, up 28%. The pharmaceutical company said the impact of Covid-19 on clinical trials in the first half has been limited, and the company remains on track to start its Phase 3 clinical trials with Ensifentrine for the treatment of chronic obstructive pulmonary disease later in 2020. The company also said it has received a notice from US Food & Drug Administration to proceed with a study of Ensifentrine in patients with Covid-19. The company plans to initiate a randomized, double-blind, placebo-controlled pilot clinical study to evaluate Ensifentrine delivered via pressurized metered-dose inhaler formulation as a treatment for patients hospitalized with Covid-19 at the University of Alabama. The study is expected to start in the third quarter of 2020. Ensifentrine is an investigational inhaled therapy that has been shown to act as both a bronchodilator and an anti-inflammatory agent in one compound.

----------

Bluejay Mining, up 12%. The miner said it completed a final public consultation meeting as part of its attempts to ink an exploitation licence for a project in Greenland. The public consultation for the Dundas ilmenite project was previously hit with delays. Due to Covid-19 affecting consultation meetings, the government of Greenland extended the consultation period from eight to 10 weeks, Dundas said in June. And in July, Bluejay had agreed an offtake deal with a "multinational commodity trading firm" at Dundas increased. The new agreement increased the amount of ilmenite to between 250,000 and 300,000 tonnes per year, extending agreement by three months to October 31.

----------

Quiz, up 8.0%. The fashion retailer said it has secured an increase and extension to its existing loan facilities from lender HSBC. The clothing company's total bank facilities has been doubled to GBP3.5 million from GBP1.8 million, comprising an overdraft facility of GBP2.0 million and a working capital facility of GBP1.5 million. The loans will remain in place until the end of October. There are no financial covenants applicable to the facilities. Quiz, which has been hammered by the Covid-19 lockdown, has GBP5.7 million in cash in addition to the loan facilities.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
13 Jan 2020 11:08

Verona Pharma shares surge after results from latest study

(Sharecast News) - Respiratory disease-focussed biopharmaceuticals company Verona Pharma announced positive top-line data from a four week, 416 patient phase 2b dose-ranging study evaluating nebulised ensifentrine or placebo as an add-on treatment to 'Spiriva Respimat', or tiotropium, which is a long acting anti-muscarinic bronchodilator, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

Read more
13 Jan 2020 10:34

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

Read more
13 Jan 2020 07:56

Verona Pharma Says Ensifentrine Study Shows Positive Results

Verona Pharma Says Ensifentrine Study Shows Positive Results

Read more
5 Nov 2019 11:29

Verona Pharma losses widen as it pours resources into ensifentrine

(Sharecast News) - Biopharmaceutical company Verona Pharma updated the market on its operations and finances for the three and nine months ended 30 September on Tuesday, highlighting positive results from the second part of its phase 2 study of the dry powder inhaler formulation of 'ensifentrine' in chronic obstructive pulmonary disorder (COPD), delivered by handheld inhaler over one week of twice-daily treatment.

Read more
5 Nov 2019 10:38

UK WINNERS & LOSERS SUMMARY: AB Foods Rises As Primark Adds US Stores

UK WINNERS & LOSERS SUMMARY: AB Foods Rises As Primark Adds US Stores

Read more
5 Nov 2019 10:15

Verona Pharma Third Quarter Loss Widens On Research & Development

Verona Pharma Third Quarter Loss Widens On Research & Development

Read more
29 Oct 2019 15:30

Inland Homes snaps up 50% stake in Cheshunt Lakeside Development

(Sharecast News) - Inland Homes on Tuesday acquired a 50% interest in joint-venture partner Cheshunt Lakeside Developments Limited that was held by CPC Group Limited.

Read more
6 Aug 2019 12:01

Verona Pharma Loss Widens In First Half On Clinical Trial Expenses

(Alliance News) - Verona Pharma PLC on Tuesday said its loss widened in the second quarter and the first half of 2019 as it progressed on clinical trials of Ensifentrine, used for the treatment of

Read more
5 Aug 2019 10:42

WINNERS & LOSERS SUMMARY: Risk-Off Trade Sends Gold Miners Higher

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 3.1%. The Mexican gold miner rose as the price of

Read more
5 Aug 2019 09:44

Verona Pharma Shares Jump 15% On Positive Ensifentrine Study Results

(Alliance News) - Verona Pharma PLC on Monday reported positive second phase test data for a dry powder inhaler formulation of its lead development product ensifentrine.The stock was 15% in

Read more
25 Jun 2019 15:31

Verona Pharma strengthens clinical team ahead of next round of trials

(Sharecast News) - Respiratory-focussed biopharmaceutical company Verona Pharma announced two senior appointments to its clinical team on Tuesday.

Read more
29 May 2019 16:23

Director dealings: Piers Morgan's spouse ups stake in Verona Pharma

(Sharecast News) - Verona Pharma revealed on Wednesday that chief financial officer Piers Morgan's wife Kayt Morgan had acquired 33,802 ordinary shares in the AIM-listed biotechnology outfit.

Read more
7 May 2019 14:41

Verona Pharma announces next study of nebulised ensifentrine

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a phase 2b dose-ranging study evaluating nebulised ensifentrine (RPL554) added on to a long-acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) on Tuesday.

Read more
9 Apr 2019 15:25

Verona Pharma Gets EU Patent For COPD Clinical Candidate Ensifentrine

LONDON (Alliance News) - Verona Pharma PLC on Tuesday said it secured a key patent from the European Patent Office relating to its lead development candidate, ensifentrine.The clinical that

Read more
9 Apr 2019 08:23

Verona Pharma gets another European patent on ensifentrine

(Sharecast News) - Respiratory disease-focussed clinical stage biopharmaceutical company Verona Pharma announced on Tuesday that the European Patent Office had granted an additional key patent relating to its lead development candidate, 'ensifentrine'.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.